Parkinson's Disease Therapeutics Market - Global Forecast 2025-2030

The Parkinson’s Disease Therapeutics Market is entering a period of rapid transformation, shaped by scientific innovation, evolving patient demands, and strategic recalibration across the healthcare value chain. Industry leaders, investors, and policy stakeholders now require clear, actionable analysis to navigate the sophisticated landscape of treatments, technologies, and emerging care models.

Market Snapshot: Parkinson’s Disease Therapeutics Market

The global Parkinson’s Disease Therapeutics Market grew from USD 5.43 billion in 2024 to USD 5.76 billion in 2025, driven by advances across drug development and care delivery. Forecasts indicate sustained growth at a CAGR of 6.29%, with the market projected to reach USD 7.83 billion by 2030. This expansion is underpinned by rising therapy adoption rates, enhanced clinical protocols, and increasing investment in disease-modifying strategies. As industry ecosystems mature, therapeutic access, value-focused reimbursement, and patient-centric innovation are reshaping commercial opportunities worldwide.

Scope & Segmentation

This research delivers in-depth coverage of the Parkinson’s Disease Therapeutics Market, analyzing industry trends, structural shifts, and growth areas across all primary segments and regions:

• Drug Class: Anticholinergics (Benztropine, Trihexyphenidyl), COMT Inhibitors (Entacapone, Tolcapone), Dopamine Agonists, Levodopa, MAO-B Inhibitors
• Therapy Type: Medications, Non-Pharmacological Therapies (Deep Brain Stimulation, Physiotherapy, Speech & Language Therapy)
• Route Of Administration: Infusion, Injectable, Oral, Transdermal
• Targeted Area: Atypical Parkinsonian, Drug-Induced Parkinsonism, Genetic Parkinson’s, Idiopathic Parkinson’s, Vascular Parkinsonism
• Distribution Channel: Offline (Hospital Pharmacy, Retail Pharmacy), Online
• End User: Clinics, Home Care, Hospitals
• Regions: Americas (United States, Canada, Mexico, Brazil, Argentina, Chile, Colombia, Peru), Europe, Middle East & Africa (United Kingdom, Germany, France, Russia, Italy, Spain, Netherlands, Sweden, Poland, Switzerland, United Arab Emirates, Saudi Arabia, Qatar, Turkey, Israel, South Africa, Nigeria, Egypt, Kenya), Asia-Pacific (China, India, Japan, Australia, South Korea, Indonesia, Thailand, Malaysia, Singapore, Taiwan)
• Company Analysis: AbbVie, Acadia Pharmaceuticals, Amneal Pharmaceuticals, Amyl Therapeutics, Apotex, Aspen Neuroscience, Biogen, Brainstorm Cell Therapeutics, Bristol-Myers Squibb, Cerevance, Denali Therapeutics, Eisai, Eli Lilly, F. Hoffmann-La Roche, GlaxoSmithKline, H. Lundbeck, Lupin, Merck & Co., Muna Therapeutics, Novartis, Orion Corporation, Otsuka, Pfizer, Sumitomo Pharma, Teva, Torrent Pharmaceuticals, UCB, Zydus Lifesciences, Bayer (for all detailed company trends)

Key Takeaways & Strategic Insights

• The market is characterized by the convergence of drug, device, and digital health innovations—providing integrated care delivery and value-added patient support.
• Therapeutic strategies are transitioning beyond traditional levodopa regimens, with greater focus on neuromodulation, continuous infusion, and precision medicine approaches.
• Industry players face increasing requirements for real-world evidence and long-term safety data, essential for payer acceptance and broad commercial uptake.
• Supply chain resilience is now a competitive differentiator—firms are diversifying sourcing strategies, leveraging dual suppliers, and enhancing inventory controls to mitigate distribution risk.
• Multidisciplinary care models and home-based interventions are gaining prominence, influencing end-user dynamics and fostering adoption of technology-enabled monitoring solutions.
• Regional disparities in reimbursement, regulatory maturity, and infrastructure demand localized market access and pricing strategies to maximize adoption and growth.

Tariff Impact & Supply Chains

Recent U.S. tariff actions have increased uncertainty across pharmaceutical and device supply chains. The consequences have been indirect, notably cost pressures on active pharmaceutical ingredients and delays in sourcing specialty components. Manufacturers are responding with geographic diversification, secondary supplier qualification, and inventory buffers. These measures safeguard distribution continuity and reduce exposure to further policy shifts.

Methodology & Data Sources

This analysis combines structured secondary research, public disclosures, and semi-structured expert interviews with neurologists, health economists, and commercial leaders. Analytical frameworks incorporate policy comparisons, qualitative synthesis, and scenario-based risk assessments. Findings are triangulated from independent industry and clinical sources to ensure robust, actionable insights. Recent events and policy shifts are incorporated via iterative review.

Why This Report Matters

• Enables leadership teams to adapt portfolios, allocate resources, and capitalize on innovation in Parkinson’s therapies
• Supports market access and pricing directors in designing localization strategies for diverse reimbursement environments
• Guides supply chain and commercial operations in building resilient, scalable distribution across priority geographies

Conclusion

This report provides concise strategic guidance grounded in clinical, commercial, and regional realities. Senior decision-makers can leverage these insights to prioritize investments, manage operational risks, and accelerate scalable patient-centric innovation in Parkinson’s care.

Additional Product Information:

• Purchase of this report includes 1 year online access with quarterly updates.
• This report can be updated on request. Please contact our Customer Experience team using the Ask a Question widget on our website.